COME TO BOOTH 2125 TO LEARN MORE ABOUT GILTERITINIB CLINICAL TRIALS EN RO SO LL ON IN G Gilteritinib (ASP2215), as Maintenance Therapy for FLT3/ITD + AML Patients in First Complete Remission 2215-CL- 0302 / NCT02927262 DESCRIPTION: A Phase 3 double-blind, multicenter, randomized, placebo-controlled study of gilteritinib (ASP2215) as maintenance therapy following induction/consolidation therapy in AML patients with FLT3/ITD first complete remission STATUS: ENROLLING SOON Gilteritinib Continuous dosing for up to 2 years AML with FLT3/ITD mutation Morphological CR1 Follow-up up to 3 years (after 30 day follow-up visit) double-blind randomization 2:1 Placebo Continuous dosing for up to 2 years AML: acute myeloid leukemia; CR1: first complete remission; FLT3: FMS-like tyrosine kinase; ITD: internal tandem duplication. PRIMARY ENDPOINT: * Relapse-free survival SECONDARY ENDPOINTS: * Overall survival * Event-free survival * Minimal residual disease SELECTION CRITERIA:a * Morphologically confirmed AML in first complete remission * Positive for FLT3/ITD mutation * Patients who will not proceed with transplantation CONTACT Astellas Pharma Global Development | 800-888-7704, ext 5473 | Astellas.registration@astellas.com The safety and efficacy of gilteritinib have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for uses being investigated. All information current as of October 2016. Not a complete list of selection criteria. a For more information, email clintrials.info@us.astellas.com Astellas® and the flying star logo are trademarks of Astellas Pharma Inc. ©2016 Astellas Pharma Global Development, Inc. All rights reserved. 071-0442-PM 10/16